| Mrs Samantha Reis, APRN, FNP-BC, CEN | |
|
5653 Mcpherson Blvd, Fort Worth, TX 76123-6023 | |
| (682) 354-3100 | |
| Not Available |
| Full Name | Mrs Samantha Reis |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 5653 Mcpherson Blvd, Fort Worth, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497317564 | NPI | - | NPPES |
| AP142039 | Other | TX | TEXAS APRN LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | AP142039 (Texas) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | AP142039 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Primary Health Physicians Pllc | 7810237740 | 146 |
News Archive
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.
An innovative mechanism that the innate immune system uses to control viral infections has been uncovered by researchers at the University Medical Centers in Mainz and Freiburg. Central to this is the discovery that two different but related elements of the immune system can act together in concert to fight, for example, rotavirus infections.
Auspex Pharmaceuticals, announced today that it has signed a deal involving a promising deuterium-containing drug with Teva Pharmaceutical Industries.
C. R. Bard, Inc. today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone. The FLAIR® Endovascular Stent Graft is the only implant approved by the U.S. Food and Drug Administration for use in the treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous access grafts.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 7 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.
An innovative mechanism that the innate immune system uses to control viral infections has been uncovered by researchers at the University Medical Centers in Mainz and Freiburg. Central to this is the discovery that two different but related elements of the immune system can act together in concert to fight, for example, rotavirus infections.
Auspex Pharmaceuticals, announced today that it has signed a deal involving a promising deuterium-containing drug with Teva Pharmaceutical Industries.
C. R. Bard, Inc. today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone. The FLAIR® Endovascular Stent Graft is the only implant approved by the U.S. Food and Drug Administration for use in the treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous access grafts.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 7 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.
An innovative mechanism that the innate immune system uses to control viral infections has been uncovered by researchers at the University Medical Centers in Mainz and Freiburg. Central to this is the discovery that two different but related elements of the immune system can act together in concert to fight, for example, rotavirus infections.
Auspex Pharmaceuticals, announced today that it has signed a deal involving a promising deuterium-containing drug with Teva Pharmaceutical Industries.
C. R. Bard, Inc. today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone. The FLAIR® Endovascular Stent Graft is the only implant approved by the U.S. Food and Drug Administration for use in the treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous access grafts.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 7 days ago
| Entity Name | Concord North Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952761173 PECOS PAC ID: 2860791688 Enrollment ID: O20160429000472 |
News Archive
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.
An innovative mechanism that the innate immune system uses to control viral infections has been uncovered by researchers at the University Medical Centers in Mainz and Freiburg. Central to this is the discovery that two different but related elements of the immune system can act together in concert to fight, for example, rotavirus infections.
Auspex Pharmaceuticals, announced today that it has signed a deal involving a promising deuterium-containing drug with Teva Pharmaceutical Industries.
C. R. Bard, Inc. today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone. The FLAIR® Endovascular Stent Graft is the only implant approved by the U.S. Food and Drug Administration for use in the treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous access grafts.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 7 days ago
| Entity Name | Apptexased Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265945539 PECOS PAC ID: 7911264296 Enrollment ID: O20171121001615 |
News Archive
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.
An innovative mechanism that the innate immune system uses to control viral infections has been uncovered by researchers at the University Medical Centers in Mainz and Freiburg. Central to this is the discovery that two different but related elements of the immune system can act together in concert to fight, for example, rotavirus infections.
Auspex Pharmaceuticals, announced today that it has signed a deal involving a promising deuterium-containing drug with Teva Pharmaceutical Industries.
C. R. Bard, Inc. today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone. The FLAIR® Endovascular Stent Graft is the only implant approved by the U.S. Food and Drug Administration for use in the treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous access grafts.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 7 days ago
| Entity Name | Primary Health Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770048704 PECOS PAC ID: 7810237740 Enrollment ID: O20190312003418 |
News Archive
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.
An innovative mechanism that the innate immune system uses to control viral infections has been uncovered by researchers at the University Medical Centers in Mainz and Freiburg. Central to this is the discovery that two different but related elements of the immune system can act together in concert to fight, for example, rotavirus infections.
Auspex Pharmaceuticals, announced today that it has signed a deal involving a promising deuterium-containing drug with Teva Pharmaceutical Industries.
C. R. Bard, Inc. today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone. The FLAIR® Endovascular Stent Graft is the only implant approved by the U.S. Food and Drug Administration for use in the treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous access grafts.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Samantha Reis, APRN, FNP-BC, CEN 7801 County Road 915b, Joshua, TX 76058-2200 Ph: (817) 907-4014 | Mrs Samantha Reis, APRN, FNP-BC, CEN 5653 Mcpherson Blvd, Fort Worth, TX 76123-6023 Ph: (682) 354-3100 |
News Archive
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.
An innovative mechanism that the innate immune system uses to control viral infections has been uncovered by researchers at the University Medical Centers in Mainz and Freiburg. Central to this is the discovery that two different but related elements of the immune system can act together in concert to fight, for example, rotavirus infections.
Auspex Pharmaceuticals, announced today that it has signed a deal involving a promising deuterium-containing drug with Teva Pharmaceutical Industries.
C. R. Bard, Inc. today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone. The FLAIR® Endovascular Stent Graft is the only implant approved by the U.S. Food and Drug Administration for use in the treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous access grafts.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 7 days ago